Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 3/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GJB2 | P29033 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18817528 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL17039969 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL5982851 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL3229210 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL24371984 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL12896363 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL23989119 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL20789103 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL20805258 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 | |
| SCHEMBL13430412 | 1.00 | HTR1A (0.46) | HTR1AALDH1A1TACR2NT5ESSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7816333-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | HTR1A 3081/4885ALDH1A1 1693/4885TACR2 2266/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | HTR1A 385/4885ALDH1A1 1208/4885TACR2 2614/4885 |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | HTR1A 3081/4885ALDH1A1 1693/4885TACR2 2266/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | HTR1A 385/4885ALDH1A1 1208/4885TACR2 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.